Abstract Background The Dapagliflozin and Prevention of Adverse outcomes in Chronic
Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the …

Background In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney
Disease (DAPA-CKD) randomized, placebo-controlled trial, the sodium-glucose …

Background Recent cardiovascular outcome trials have shown that sodium–glucose co-
transporter 2 (SGLT2) inhibitors slow the progression of chronic kidney disease (CKD) in …

Background The DAPA‐CKD (Dapagliflozin and Prevention of Adverse Outcomes in
Chronic Kidney Disease) trial (NCT03036150) demonstrated that dapagliflozin reduced the …

Abstract Aims/hypothesis In the Dapagliflozin and Prevention of Adverse Outcomes in
Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive …

OBJECTIVE The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney
Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular …

Background: Dapagliflozin reduces the risk of end-stage renal disease in patients with
chronic kidney disease. We examined the relative risk of cardiovascular and renal events in …

Background Patients with chronic kidney disease have a high risk of adverse kidney and
cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease …

Background Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney
disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified …

This pre-specified analysis of DAPA-CKD assessed the impact of sodium-glucose
cotransporter 2 inhibition on abrupt declines in kidney function in high-risk patients based on …